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Cardiac Biomarkers and Subsequent Risk of Hospitalization
With Bleeding in the Community: Atherosclerosis Risk in
Communities Study
Lena Mathews, MD, MHS; Junichi Ishigami, MD, MPH; Ning Ding, MD, ScM; Ron C. Hoogeveen, PhD; Anna Kucharska-Newton, PhD, MPH;
Christie M. Ballantyne, MD; Rebecca Gottesman, MD, PhD; Elizabeth Selvin, PhD, MPH; Kunihiro Matsushita , MD, PhD
Background-—hs-cTnT (high-sensitivity cardiac troponin T), but not NT-proBNP (N-terminal pro–B natriuretic peptide), has been
shown to predict bleeding in patients with atrial fibrillation. Whether these biomarkers are independently associated with bleeding
in the general population is unknown.
Methods and Results-—We used Cox proportional hazards models to examine the association of hs-cTnT and NT-proBNP with
incident bleeding (defined by International Classification of Diseases, Ninth Revision [ICD-9] codes) among 9550 middle-aged men
and women without a history of cardiovascular disease or bleeding. There were 847 hospitalizations with bleeding (92% from
gastrointestinal bleeding) during a median follow-up of 9.0 years. Serum levels of hs-cTnT were associated with bleeding in a
graded fashion, with a hazard ratio of 1.28 (95% CI, 1.06–1.59) for 6 to <9 ng/L, 1.52 (1.21–1.91) for 9 to <14, and 2.05 (1.56–
2.69) for ≥14 versus <3 ng/L. For NT-proBNP, the highest category (≥264 versus <42 pg/mL) showed a hazard ratio of 2.00
(1.59–2.61), and the remaining 3 categories had hazard ratios ranging from 1.2 to 1.3. Individuals in the highest category of both
hs-cTnT and NT-proBNP had a hazard ratio of 3.03 (1.97–4.68) compared with those in the lowest categories.
Conclusions-—In a community-based population, elevated hs-cTnT and NT-proBNP were associated with bleeding-related
hospitalizations. These biomarkers may have a high utility in identifying people at high risk for bleeding. There is a need for
research on the underlying mechanisms linking subclinical cardiac abnormalities and bleeding. ( J Am Heart Assoc. 2020;9:
e013560. DOI: 10.1161/JAHA.119.013560.)
Key Words: bleeding • cardiac troponin T • gastrointestinal bleeding • natriuretic peptide
M ajor bleeding events are associated with substantialmorbidity, mortality, and medical costs.1 Factors that
are associated with bleeding may elucidate the mechanistic
causes of bleeding events, identify individuals at high risk, and
potentially guide clinical management (eg, select antithrom-
botic medications with lower risk of bleeding). Several
predictors of bleeding have been reported, including age,
female sex, chronic kidney disease, liver disease, prior stroke,
bleeding history, and excessive alcohol use.2,3
A few studies have shown that hs-cTnT (high-sensitivity
cardiac troponin T), a biomarker associated with myocardial
injury,4 is a potent predictor of bleeding. For example, hs-
cTnT predicted recurrences of bleeding in an observational
study of patients with gastrointestinal bleeding.5 In addition,
peak troponin levels were associated with an increased risk
of bleeding in patients with acute coronary syndrome.6
Furthermore, 2 large clinical trials: ARISTOTLE (Apixaban for
Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation) and RE-LY (Randomized Evaluation of Long-
Term Anticoagulation Therapy) showed an independent
association of hs-cTnT with incident major bleeding in
individuals with atrial fibrillation on anticoagulation ther-
apy.7-10 A bleeding risk score that included age, biomarkers
(hemoglobin, growth differentiating factor-15, and hs-cTnT),
and history of bleeding, known as the “ABC bleeding score,”
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was derived and validated in these large studies and was
shown to better predict bleeding events in individuals with
atrial fibrillation compared with other bleeding risk scores
such as the HAS-BLED (Hypertension, Abnormal Renal or
Liver Function, Stroke, Bleeding, Labile INR, Elderly, Prior
Drug or Alcohol Usage) or ORBIT (Outcomes Registry for
Better Informed Treatment) scores that are based on clinical
characteristics.10
There are a few plausible mechanisms underlying the
association of hs-cTnT with bleeding. Elevated hs-cTnT and
bleeding may share some risk factors such as diabetes
mellitus and hypertension.11,12 In addition, hs-cTnT may
reflect subclinical cardiac abnormalities resulting in elevated
venous pressure and increased bleeding risk.13 Moreover,
there is growing literature on the association of hs-cTnT with
markers of subclinical microvascular disease in a variety of
organs including the brain and kidney.4,14 Thus hs-cTnT may
reflect systemic and subclinical small-vessel disease including
in the gastrointestinal tract and may be associated with an
elevated risk of bleeding.15
No studies have assessed whether hs-cTnT is prospectively
associated with bleeding in the general population. Because
some investigators propose using hs-cTnT for predicting
incident cardiovascular events,16,17 it would be important to
quantify the value of hs-cTnT for predicting bleeding events as
well. Although the benefit and harm of antiplatelet therapy for
cardiovascular disease prevention are controversial,18-20 and
some expert organizations such as the US Preventive Services
Task Force recommend aspirin for some individuals,21 such
quantification will have clinical implications. Therefore, we
investigated whether elevations of hs-cTnT were prospectively
associated with bleeding events among individuals without a
history of cardiovascular disease in the ARIC (Atherosclerosis
Risk in Communities) study. We also evaluated whether this
association was also present for NT-proBNP (N-terminal pro–
B-type natriuretic peptide), a marker of myocardial wall stress
and volume overload. In ARISTOTLE and RE-LY, NT-proBNP
was not a predictor of bleeding among atrial fibrillation
patients.8,10
Methods
The study data will not be made available to other researchers
for the purposes of reproducing the results or replicating the
procedure because of human subject restrictions. However,
interested investigators can request access to the ARIC study
data by contacting the ARIC Study Coordinating Center at the
University of North Carolina–Chapel Hill.22
Study Population
We used data from the ARIC Study, a prospective cohort study
of 15 792 individuals aged 45 to 64 years from 4 commu-
nities in the United States (Forsyth County, NC; Jackson, MS;
suburban Minneapolis, MN; Washington County, MD) enrolled
between 1987 and 1989.23 Three follow-up visits (visits 2 to
4) took place approximately every 3 years, and subsequent
visits 5 and 6 during 2011 to 2013 and 2016 to 2017,
respectively. Phone interviews were conducted annually and
semiannually from 2012. We used visit 4 (1996-1998) as our
baseline because of the availability of albuminuria, a predictor
of bleeding,24 a higher prevalence of elevated hs-cTnT and NT-
proBNP, and bleeding events. Out of 11 656 participants in
visit 4, we excluded individuals with a prior history of bleeding
(n=235), prevalent coronary heart disease (CHD) or stroke
(n=1148), nonwhite and nonblack individuals (n=28), those
who received blood transfusions (n=2), and those missing
baseline covariates, hs-cTnT, and NT-proBNP (n=693),
leaving 9550 individuals in the study who participated in
visit 4 (Figure 1). A history of CHD was defined as a self-
reported history of myocardial infarction or prior coronary
Clinical Perspective
What Is New?
• In this long-term prospective study of 9550 individuals in
the Atherosclerosis Risk in Communities study without
known cardiovascular disease or bleeding history, subclin-
ical elevations of high-sensitivity cardiac troponin T, a
marker of myocardial injury, and N-terminal pro–B natri-
uretic peptide, a marker of myocardial wall stress, were
associated with an increased risk of hospitalization with
bleeding.
• Both high-sensitivity cardiac troponin T and N-terminal pro–
B natriuretic peptide significantly improved the risk discrim-
ination of bleeding beyond established clinical predictors of
bleeding.
What Are the Clinical Implications?
• For those individuals with elevated high-sensitivity cardiac
troponin T and/or N-terminal pro–B natriuretic peptide at
risk of both cardiovascular disease events and bleeding,
primary prevention should prioritize therapies that do not
increase the risk for bleeding such as statins, blood
pressure control, and diabetes mellitus control.
• For people at high cardiovascular risk due to traditional risk
factors but at lower risk of bleeding represented by low
levels of high-sensitivity cardiac troponin T and N-terminal
pro–B natriuretic peptide, preventive antiplatelet therapy
may be a reasonable option when indicated.
• Future studies may be necessary to confirm the risk
prediction improvement of bleeding with these cardiac
biomarkers in other settings.
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revascularization at visit 1, evidence of silent myocardial
infarction on electrocardiogram, or an adjudicated CHD event
between visits 1 and 4.25 A history of stroke was defined as a
self-reported history of stroke at visit 1 or an adjudicated
ischemic stroke event between visits 1 and 4.26 The
institutional review boards of all participating centers
approved the research protocol, and all participants provided
written informed consent. The study complied with the
Declaration of Helsinki.
Cardiac Biomarkers
Hs-cTnT was measured in 2010-2011 from plasma samples
collected at Visit 4 using a Cobas e411 analyzer (Roche
Diagnostics, Indianapolis, IN) and stored at –70°C. The limit of
blank was 3 ng/L, the limit of detection was 5 ng/L, and the
upper reference limit of ≥14 ng/L corresponded to the 99th
percentile in healthy individuals.27 For participants with hs-
cTnT below the detectable threshold, we assigned a value of
1.5 ng/L.28 The coefficient of variation was 10% at 13 ng/L.29
NT-proBNP was also measured from plasma samples on the
Cobas e411 analyzer (Roche Diagnostics, Basel, Switzerland)
using the Elecsys NT-proBNP assay. The lower limit of
detection was 5 pg/mL.30 For participants with NT-
proBNP below the detectable threshold, we assigned a value
of 2.5 pg/mL.30,31
Definition of the Outcome
The outcome of hospitalization with bleeding was identified
from hospital International Classification of Disease, Ninth
Revision (ICD-9) discharge codes at any position through
December 31, 2013 and was defined as cases with a
hospital discharge diagnosis of gastrointestinal, intracranial,
or retroperitoneal bleeding and blood transfusions
(Table S1).24,32 Participants were followed until incident
bleeding hospitalization, death, loss to follow up, or the end of
follow-up.
Covariates
Baseline demographics, lifestyle factors, and clinical charac-
teristics were obtained at visit 4, except education, which was
obtained at visit 1. Education was categorized as basic
Figure 1. Derivation of the study population, the ARIC Study (N=9550). ARIC indicates Atherosclerosis Risk in Communities; hs-cTnT, high-
sensitivity cardiac troponin T; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
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education (<high school), intermediate education (high school
graduate or vocational school), and advanced education
(college, graduate, or professional school).27 Participants
reported their use of medications over the previous 2 weeks,
and medication bottles were inspected at the study visit.
Aspirin, NSAIDs, and anticoagulants were also examined at
visit 5 and during phone interviews. Self-reported cigarette
use was categorized as current, former, or never smoker. Self-
reported alcohol use was categorized as current drinker
(presently consuming alcoholic beverages), former drinker
(previously but not currently consuming alcoholic beverages),
and never drinker. Body mass index was defined as weight in
kilograms divided by height in meters squared. Sitting blood
pressure was measured twice using a sphygmomanometer,
and the mean of the 2 measurements was recorded.
Hypertension was defined as a systolic blood pressure
≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or the
use of blood pressure–lowering medications. Diabetes melli-
tus was defined as having a fasting glucose ≥126 mg/dL,
random glucose ≥200 mg/dL, self-reported physician diag-
nosis of diabetes mellitus, or antidiabetic medication use.
History of bleeding or cancer was obtained from hospital
records based on ICD-9 discharge codes. Estimated glomeru-
lar filtration rate was calculated using the Chronic Kidney
Disease Epidemiology Collaboration creatinine equation.33
Urine albumin-creatinine ratio was used as a measure of
albuminuria.34 Total cholesterol was measured by enzymatic
methods, and high-density lipoprotein cholesterol was mea-
sured after dextran-magnesium precipitation of non–high-
density lipoprotein particles.35 Alanine aminotransferase and
aspartate aminotransferase were measured at visit 4. History
of hepatic failure was defined as 3 times the upper limit of
normal of alanine aminotransferase or aspartate aminotrans-
ferase or an ICD-9 diagnosis of liver cirrhosis.24 Incident CHD
and stroke events were adjudicated by physician panels.
Statistical Analysis
Hs-cTnT levels were divided into 5 categories27: <3 (refer-
ence), 3 to <6, 6 to <9, 9 to <14, and ≥14 ng/L
(corresponding to the 99th percentile in healthy individuals).
NT-proBNP levels were also divided into 5 categories based
on the same percentiles as hs-cTnT: <42 (reference), 42 to
<81, 81 to <140, 140 to <264, and ≥264 pg/mL. Baseline
characteristics were summarized across the 5 categories of
hs-cTnT and NT-proBNP separately and were compared using
ANOVA for continuous variables and a chi-squared test for
categorical variables.
We used Poisson regression models to estimate the
incidence rate of bleeding adjusted for age, sex, and race
according to natural log–transformed hs-cTnT and NT-proBNP
values. We used linear splines with 4 knots corresponding to the
thresholds for the 5 biomarker categories and, trimmed at the
99.5th percentile for data presentation. We used multivariable
Cox proportional hazards models to evaluate the association of
hs-cTnT and NT-proBNP with incident hospitalization with
bleeding. The cardiac biomarkers were modeled categorically
and continuously (after log transformation). Model 1 was
adjusted for age, race, sex, education, body mass index,
diabetes mellitus, systolic blood pressure, cigarette use, alcohol
use, total cholesterol, high-density lipoprotein cholesterol,
aspirin use, anticoagulation use, NSAID use, antihypertensive
use, statin use, estimated glomerular filtration rate, albumin-
creatinine ratio, and liver function markers (alanine aminotrans-
ferase and aspartate aminotransferase). Aspirin, anticoagulants,
and NSAIDs were modeled as time-varying covariates. Model 2
was adjusted for all variables in model 1 plus cardiac biomarkers
(hs-cTnT in the NT-proBNP analysis and vice versa). Model 3 was
adjusted for all variables in model 2 plus incident atherosclerotic
cardiovascular disease (CHD and stroke) events occurring
during follow-up modeled as time-varying covariates. Specifi-
cally, participants who developed CHD or stroke before bleeding
had 2 rows in the data set. The first row was for the status of no
CHD or stroke and the follow-up time until the development of
atherosclerotic cardiovascular disease, and the second row was
for the status of prevalent CHD or stroke and the follow-up time
after atherosclerotic cardiovascular disease through censoring
or bleeding. We used log Nelson-Aalen cumulative hazard plots
and confirmed that the proportional hazard assumptions were
met.
We performed several sensitivity analyses. First, we
restricted our analysis to bleeding events as the primary
discharge diagnosis. Second, we evaluated a joint association
of hs-cTnT and NT-proBNP by analyzing their cross-categories.
Third, we performed subgroup analysis by stratifying by age
(<60 versus ≥60 years), sex, race (black versus white),
current smoker, hypertension (yes versus no), diabetes
mellitus (yes versus no), use of aspirin (yes versus no), and
anticoagulation (yes versus no). Fourth, we performed anal-
ysis including participants with a prior history of bleeding at
baseline. Lastly, we assessed the improvement in risk
prediction beyond established predictors of bleeding using a
base model consisting of predictors of bleeding in the HAS-
BLED score (hypertension, abnormal liver/kidney function,
age >65 years, drugs associated with bleeding, excess
alcohol use defined as >8 drinks per week, and incident
stroke).3 Prior stroke and bleeding were included in the HAS-
BLED score but were not taken into account in our analysis
because individuals with a history of these conditions had
been excluded from the baseline characteristics. However, we
accounted for incident stroke during follow-up. We used the
Harrell c statistic to measure the discrimination and esti-
mated its change with the addition of log-transformed hs-cTnT
and/or NT-proBNP to the base model.
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A 2-sided P<0.05 was considered statistically significant.
All statistical analyses were performed using Stata 15.1
(StataCorp, College Station, TX).
Results
Baseline Characteristics
Compared with individuals with undetectable hs-cTnT, those
with progressively higher hs-cTnT levels were older, were
more likely to be black, male, have a more basic or lower
education level, a higher body mass index, were more likely to
be former smokers (current smoking had a J-shaped associ-
ation), more likely to be former drinkers (current drinking was
inversely associated), more likely to have diabetes mellitus,
hypertension, worse kidney function, higher alanine amino-
transferase, aspartate aminotransferase, and NT-proBNP, and
to use anticoagulants (Table 1). The baseline characteristics
of the study participants according to NT-proBNP levels
showed similar patterns to those for hs-cTnT except for the
following: progressively higher NT-proBNP was more likely
associated with female sex, white race, higher hs-cTnT, lower
body mass index, current smoking, and never having used
alcohol (Table S2).
Association of Cardiac Biomarkers With Bleeding
Among the study participants, 847 experienced hospitalized
bleeding events during a median of 9.0 years of follow-up
(maximum 17.7 years). Of those events, 433 (51%) had a
primary diagnosis of bleeding. Gastrointestinal was the
predominant type of bleeding (781 events [92%]), followed
by intracranial (49 events [5.8%]) and retroperitoneal (31
events [3.7%]). The association of continuous hs-cTnT and NT-
proBNP with the incidence rate for bleeding adjusted for age,
sex, and race are shown in Figures 2A and 2B, respectively.
The incidence rate for bleeding increased largely linearly with
higher levels of log-transformed biomarkers, with an approx-
imately 3-fold risk gradient in the range below their 99.5th
percentile.
In multivariable adjusted models, compared with individu-
als with hs-cTnT <3 ng/L, there was an increasing risk of
bleeding in a graded fashion with a hazard ratio (HR) of 1.28
(95% CI, 1.06–1.59) for 6 to <9 ng/L, 1.52 (1.21–1.91) for 9
to <14 ng/L, and 2.05 (1.56–2.69) for ≥14 ng/L (model 1,
Table 2). Further accounting for NT-proBNP (model 2) or
incident stroke and CHD during follow-up as a time-varying
covariate (model 3) did not substantially alter the results.
Continous log-transformed hs-cTnT was associated with an
increased hazard for bleeding in the fully adjusted model.
Similarly, higher NT-proBNP was associated with increasing
risk of bleeding (model 1, Table 2). The highest category of
NT-proBNP demonstrated a similar HR as the highest category
of hs-cTnT with HR 2.14 (1.65–2.79). The lower NT-proBNP
categories showed HRs of 1.2 to 1.3. The results remained
consistent even after adjustment for hs-cTnT (model 2) or
incident cardiovascular disease during follow-up (model 3).
Continuous log-transformed NT-proBNP was associated
with an increased hazard for bleeding in the fully adjusted
model.
The results were generally consistent in cases in which
bleeding was the primary discharge diagnosis (Table S3) and
when we examined the association by type of bleeding
diagnosis (Table S4). We found similar results when we
included individuals who had a prior history of bleeding and
further adjusted for a history of bleeding (Table S5). There
were no significant interactions between bleeding and a 2-fold
increase in both biomarkers by race, sex, and different clinical
risk factors. The association was similar among those with
and without treatment with aspirin and anticoagulation
(Figure 3A and 3B).
When cross-categories of hs-cTnT and NT-proBNP were
studied, we found that individuals with both the highest hs-
cTnT (≥14 ng/L) and NT-proBNP (≥264 pg/mL) categories
had a HR of 3.03 (1.97–4.68) for bleeding compared with the
lowest category with hs-cTnT (<6 ng/L) and NT-proBNP
(<80 pg/mL) (Table 3). In addition, subclinical elevation of
both hs-cTnT (6 to <14 ng/L) and NT-proBNP (80 to
<264 pg/mL) had a HR 1.62 (1.28–2.05). Subclinical eleva-
tion of hs-cTnT alone (with NT-proBNP <80 pg/mL) demon-
strated a significant HR of 1.48 (1.20–1.83), but subclinical
elevation of NT-proBNP alone (80 to <264 pg/mL with hs-
cTnT <6 ng/L) did not evidently confer an increased bleeding
risk (HR 1.06).
Risk Discrimination by Adding Cardiac
Biomarkers
The base model with predictors in the HAS-BLED score
showed a c-statistic of 0.640 for bleeding (Table 4). The
addition of hs-cTnT alone improved the c-statistic by 0.011
(0.006–0.016), and the addition of NT-proBNP alone improved
the c-statistic by 0.009 (0.004–0.013). When both cardiac
biomarkers were included, the improvement of the c-statistic
was 0.015 (0.009–0.020).
Discussion
In this community-based study, higher baseline levels of hs-
cTnT and NT-proBNP were independently and robustly asso-
ciated with the risk of hospitalizations with bleeding. Each of
the highest biomarker categories (hs-cTnT ≥14 ng/L and NT-
proBNP ≥264 pg/mL) conferred a nearly 2-fold increase in
DOI: 10.1161/JAHA.119.013560 Journal of the American Heart Association 5
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the hazard for bleeding. Even subclinical elevation of hs-cTnT
of 9 to <14 ng/L contributed an approximately 1.5 times
higher risk of bleeding. The associations were consistent after
accounting for incident atherosclerotic cardiovascular disease
during follow-up and across demographic and clinical sub-
groups. Importantly, both hs-cTnT and NT-proBNP significantly
improved risk discrimination of bleeding beyond its estab-
lished predictors.
Table 1. Baseline Characteristics According to Categories of hs-cTnT in the ARIC Study (1996-1998) (N=9550)
Baseline Characteristics hs-cTnT <3 ng/L hs-cTnT 3 to <6 ng/L hs-cTnT 6 to <9 ng/L hs-cTnT 9 to <14 ng/L hs-cTnT ≥14 ng/L P Value
No. of participants 3240 2456 1947 1233 674
Age, y 60.6 (5.0) 62.4 (5.5) 63.6 (5.5) 65.0 (5.6) 65.3 (5.7) <0.001
Female 78.7% 61.9% 46.9% 35.0% 26.0% <0.001
Black 21.4% 18.6% 21.7% 23.2% 28.5% <0.001
Body mass index, kg/m2 28.2 (5.5) 28.5 (5.5) 29.0 (5.6) 29.4 (5.4) 29.7 (5.5) <0.001
Education level
Basic 15.1% 17.2% 17.6% 22.5% 24.9% <0.001
Intermediate 45.3% 43.0% 41.2% 37.2% 36.9%
Advanced 39.6% 39.9% 41.2% 40.3% 38.1%
Family history of CAD 54.5% 57.2% 58.9% 57.1% 55.0% 0.028
Smoking status
Current smokers 20.7% 12.7% 9.7% 9.9% 12.9% <0.001
Former smokers 36.4% 41.6% 45.6% 49.1% 50.0%
Never smokers 42.9% 45.7% 44.6% 40.9% 37.1%
Drinking status
Current drinkers 52.4% 53.1% 49.2% 46.6% 45.1% <0.001
Former drinkers 27.0% 26.5% 29.2% 30.3% 35.8%
Never drinkers 20.6% 20.4% 21.6% 23.1% 19.1%
NT-proBNP, pg/mL, median (IQR) 59.2 (29.6, 106.8) 61.9 (31.6, 113.5) 61.9 (30.7, 122.4) 71.7 (36.1, 147.1) 96.0 (44.2, 263.6) <0.001
Systolic blood pressure, mm Hg 124.3 (17.8) 126.3 (18.1) 128.3 (18.6) 131.6 (19.9) 132.7 (20.7) <0.001
Total cholesterol, mmol/L 5.3 (0.9) 5.2 (0.9) 5.2 (1.0) 5.1 (1.0) 5.0 (1.0) <0.001
HDL cholesterol, mmol/L 1.4 (0.4) 1.3 (0.4) 1.3 (0.4) 1.2 (0.4) 1.2 (0.4) <0.001
eGFR categories in mL/min per 1.73 m2
<30 0.03% 0.04% 0.10% 0.32% 2.4% <0.001
30 to 60 2.6% 4.1% 6.5% 10.1% 18.0%
>60 97.4% 95.9% 93.4% 89.6% 79.7%
AST, U/L, median (IQR) 17.0 (15.0-21.0) 18.0 (15.0-21.0) 18.0 (16.0-22.0) 19.0 (16.0-22.0) 20 (16.0-24.0) <0.001
ALT, U/L, median (IQR) 12.0 (9.0-16.0) 13.0 (10.0-17.0) 14.0 (10.0-18.0) 14.0 (10.0-18.0) 14.0 (10.0-20.0) <0.001
Medication use
Hypertension medications 27.7% 30.0% 36.7% 40.4% 49.6% <0.001
Aspirin 53.6% 54.3% 53.9% 55.8% 57.1% 0.4
Statin 8.7% 8.4% 8.6% 10.5% 11.4% 0.04
Anticoagulant 0.5% 0.7% 1.2% 2.2% 5.2% <0.001
Diabetes mellitus 9.8% 11.9% 16.7% 20.8% 34.4% <0.001
History of hepatic failure 0.2% 0.3% 0.5% 0.2% 0.3% 0.4
History of cancer 7.6% 8.2% 7.5% 8.8% 8.9% 0.5
Values are mean (SD) or percentage, unless otherwise indicated. ALT indicates alanine aminotransferase; ARIC, Atherosclerosis Risk in Communities; AST, aspartate aminotransferase;
CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hs-cTnT, high-sensitivity cardiac troponin T; IQR, interquartile range; NT-proBNP, N-
terminal pro–B-type natriuretic peptide.
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Our results for hs-cTnT are consistent with previous
findings in populations with a history of atrial fibrillation on
oral anticoagulation in the RE-LY and ARISTOTLE studies.8-10
However, our study is unique in several aspects. First, we
confirmed hs-cTnT was a predictor of bleeding in the general
population. Second, we had follow-up over 17 years (<2 years
in RE-LY and ARISTOTLE).10 Third, we confirmed that the
association of hs-cTnT with bleeding was consistent across
several demographic and clinical subgroups. Importantly,
significant association between hs-cTnT and bleeding was
seen among those with or without aspirin and those who did
not take anticoagulants. Finally, unlike the results from RE-LY
and ARISTOTLE, in addition to hs-cTnT, we found an
association between elevated NT-proBNP and a subsequent
risk of bleeding, with a slightly weaker or similar magnitude as
hs-cTnT particularly in the clinically elevated range.
Although we are not sure about the exact mechanism for
the association of elevated hs-cTnT with bleeding, there are
some potential mechanisms to consider. First, this may be
due to imbalance in the use of aspirin or anticoagulation
Figure 2. Incidence rates (95% CI) for the association of baseline categories of natural log–transformed (A) hs-cTnT (ng/L) and (B) NT-proBNP
(pg/mL) with incident hospitalizations for bleeding in the ARIC study (N=9550). The solid line indicates the point estimate, the shaded area is
95% CI. The results are adjusted for age, sex, and race. The knots correspond to the thresholds for the 5 biomarker categories, trimmed at the
99.5th percentile. ARIC indicates Atherosclerosis Risk in Communities; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro–
B-type natriuretic peptide.
Table 2. Adjusted HRs (95% CIs) for the Association of Baseline Categories and Log-Transformed hs-cTnT and NT-proBNP With
Incident Hospitalizations for Bleeding, from the ARIC Study
hs-cTnT (ng/L)
log hs-cTnT<3 3 to <6 6 to <9 9 to <14 ≥14
Model 1 Reference 0.80 (0.64–0.98) 1.28 (1.06–1.59) 1.52 (1.21–1.91) 2.05 (1.56–2.69) 1.28 (1.17–1.41)
Model 2 Reference 0.79 (0.64–0.98) 1.29 (1.05–1.59) 1.52 (1.21–1.91) 1.99 (1.51–2.61) 1.26 (1.14–1.38)
Model 3 Reference 0.78 (0.63–0.96) 1.30 (1.06–1.59) 1.50 (1.19–1.89) 1.95 (1.48–2.56) 1.25 (1.14–1.38)
NT-proBNP (pg/mL)
log NT-proBNP<42 42 to <81 81 to <140 140 to <264 ≥264
Model 1 Reference 1.23 (1.02–1.55) 1.27 (1.02–1.57) 1.29 (1.01–1.65) 2.14 (1.65–2.79) 1.18 (1.10–1.27)
Model 2 Reference 1.28 (1.02–1.55) 1.26 (1.02–1.57) 1.29 (1.01–1.64) 2.12 (1.62–2.76) 1.18 (1.10–1.27)
Model 3 Reference 1.26 (1.01–1.53) 1.24 (1.00–1.54) 1.27 (0.99–1.62) 2.00 (1.59–2.61) 1.16 (1.08–1.25)
Model 1 adjusted for age, sex, race, education, BMI, diabetes mellitus, family history of coronary artery disease, systolic blood pressure, cigarette use, alcohol use, total cholesterol, HDL
cholesterol, statin use, aspirin, anticoagulation, NSAID, antihypertensive, eGFR, ACR, AST, ALT. Model 2 adjusted for variables in model 1 and for hs-cTnT or NT-proBNP. Model 3 adjusted
for variables in model 2 and incident stroke and coronary heart disease. ACR indicates albumin-creatinine ratio; ALT, alanine aminotransferase; ARIC, Atherosclerosis Risk in Communities;
AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac
troponin T; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
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across hs-cTnT categories. However, we excluded those with
prevalent CHD, and this significant association between hs-
cTnT and bleeding persisted after adjustment for incident
CHD and time-varying aspirin, NSAID, and anticoagulant use.
Second, both subclinical myocardial damage and gastroin-
testinal bleeding have multiple shared risk factors including
smoking,36 age,36 hypertension,11 and diabetes mellitus.12
However, again, the association was independent of these
potential confounders. Third, hs-cTnT has been associated
with incident heart failure,37 and may be a marker of
subclinical elevation of venous filling pressure that may lead
to gastrointestinal mucosal congestion and bleeding.13
Finally, another possibility may be related to recent findings
indicating that hs-cTnT is a marker of microvascular disease in
several organs including the brain and kidneys.4,15,38
Microvascular disease may result in fragile vessels in the
gastrointestinal tract that make them more prone to bleeding
Figure 3. Adjusted HRs (95% CIs) for bleeding according to a 2-fold increase in (A) hs-cTnT (ng/L) and (B) NT-proBNP (pg/mL). The models are
adjusted for age, sex, race, education, BMI, diabetes mellitus, systolic blood pressure, cigarette use, alcohol use, total cholesterol, HDL
cholesterol, aspirin, anticoagulation, NSAID, antihypertensive medication, eGFR, ACR, AST, ALT, hs-cTnT, and NT pro-BNP. ACR indicates
albumin-creatinine ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular
filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro–B-type
natriuretic peptide.
Table 3. Adjusted HRs (95% CIs) for the Association of
Baseline Cross-Categories of hs-cTnT and NT-proBNP With
Incident Hospitalizations for Bleeding, From the ARIC Study
hs-cTnT
<6 ng/L 6-<14 ng/L ≥14 ng/L
NT-proBNP
<80 pg/mL Reference 1.48 (1.20–
1.83)
2.19 (1.52–
3.16)
80 to <264 pg/mL 1.06 (0.85–
1.33)
1.62 (1.28–
2.05)
1.99 (1.33–
2.98)
≥264 pg/mL 1.37 (0.90–
2.09)
2.31 (1.64–
3.25)
3.03 (1.97–
4.68)
Model adjusted for age, sex, race, education, BMI, diabetes mellitus, family history of
coronary artery disease, systolic blood pressure, cigarette use, alcohol use, total
cholesterol, HDL cholesterol, aspirin, anticoagulation, NSAID, antihypertensive, eGFR,
ACR, AST, ALT, incident stroke, coronary heart disease. ACR indicates albumin-creatinine
ratio; ALT, alanine aminotransferase; ARIC, Atherosclerosis Risk in Communities; AST,
aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration
rate; HDL, high-density lipoprotein; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac
troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide.
Table 4. c-Statistic Improvement by Adding hs-cTnT and/or
NT-proBNP to Established Bleeding Score HAS-BLED Score
Harrell c (95% CI)
c-Statistic
Difference From
Base Model
(95% CI)
P Value for
Difference
Base model 0.640 (0.617–
0.663)
. . . . . .
+Log hs-cTnT 0.651 (0.629–
0.674)
0.011 (0.006–
0.016)
<0.001
+Log NT-proBNP 0.649 (0.626–
0.671)
0.009 (0.004–
0.013)
<0.001
+Log hs-cTnT
+log NT-
proBNP
0.654 (0.632–
0.677)
0.015 (0.009–
0.020)
<0.001
The base model includes predictors of bleeding based on the HAS-BLED Score and the
improvement in risk prediction of bleeding with cardiac biomarkers added to the HAS-
BLED score. Uncontrolled hypertension defined as systolic blood pressure >160 mm Hg;
severe kidney disease defined as eGFR <30 mL/min per 1.73 m2; liver disease defined as
the presence of liver cirrhosis and esophageal varices without bleeding from ICD-9
discharge codes; excess alcohol use defined as greater than 8 drinks per week, naturally
log-transformed hs-cTnT in ng/L and NT-proBNP per 1000 pg/mL (prior bleeding, labile
INR excluded). eGFR indicates estimated glomerular filtration rate; hs-cTnT, high-sensitivity
cardiac troponin T; ICD-9, International Classification of Diseases, Ninth Revision; INR,
international normalized ratio; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
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and decrease healing of mucosal injuries.11,39,40 Nonetheless,
given consistent observations about the TnT-bleeding rela-
tionship in different settings, future research is needed to
understand potential mechanisms.
As noted above, the association of NT-proBNP with
bleeding was contrary to prior null findings in RE-LY and
ARISTOTLE.8,10 This discrepancy may be due to the difference
in study populations. Specifically, RE-LY and ARISTOTLE
enrolled patients with atrial fibrillation on anticoagulation,
whereas our study was community based. However, in
subgroup analyses, our results similarly did not show an
association of NT-proBNP with bleeding in patients on
anticoagulation. In addition, it is possible that many patients
in RE-LY and ARISTOTLE had more comorbidities including
heart failure (30% to 40% of patients in these 2 trials had heart
failure), and thus, NT-proBNP might not efficiently discrimi-
nate the bleeding risk in this population with higher comor-
bidities. Thus, the risk of bleeding associated with NT-proBNP
may be more relevant in individuals expected to have lower
NT-proBNP, specifically those without cardiovascular disease.
In terms of a potential mechanism, elevated NT-proBNP also
reflects elevated filling pressures that lead to changes in the
gastrointestinal vasculature including angiodysplasia,41 muco-
sal congestion,42 activated fibrinolytic pathways, and then
potentially to increased gastrointestinal bleeding. Neverthe-
less, studies are needed to replicate the association between
natriuretic peptides and a subsequent risk of bleeding in the
general population.
The addition of both cardiac biomarkers to established
bleeding predictors significantly improved the prediction of
bleeding. Although the range in the change of the c-statistic
with the addition of hs-cTnT, NT-proBNP, or both biomarkers
was modest (0.009 to 0.015) and may look small, this level of
discrimination improvement was actually higher than those of
established bleeding predictors such as uncontrolled hyper-
tension (Dc-statistic 0.006), estimated glomerular filtration
rate <30 mL/min per 1.73 m2 (0.006), and the use of aspirin
or anticoagulation (0.008). Of note, there may be clinical
scenarios where data on hs-cTnT and NT-proBNP are already
available, and in such circumstances, our results suggest that
taking into account these cardiac biomarkers would lead to
improved prediction of bleeding risk. Nonetheless, future
studies may be necessary to confirm the improvement in risk
prediction of bleeding with these cardiac biomarkers in other
settings.
There are a few potential implications of our study. First,
our results suggest that these 2 cardiac biomarkers may be
helpful in classifying the risk of bleeding. Aspirin use for
primary cardiovascular disease prevention in select patients
with high risk is associated with substantial reduction in
adverse cardiovascular outcomes but with an increased risk
of major bleeding events.20 Balancing the benefits and harm
of cardiovascular disease with primary preventive therapies is
crucial and often challenging. In this context our observation
of high bleeding risk in individuals with elevated hs-cTnT and/
or NT-proBNP indicates complexity in the decision to use
antiplatelet therapy for primary cardiovascular prevention
because those individuals are known to be at high risk of
cardiovascular disease events as well. Nonetheless, for those
individuals at risk of both cardiovascular disease events and
bleeding, an option is to prioritize cardiovascular disease
prevention that does not further increase the risk for
bleeding, such as statins, blood pressure control, and
diabetes mellitus control as appropriate. On the other hand,
for those at high cardiovascular risk due to traditional risk
factors but at lower risk of bleeding represented by low levels
of hs-cTnT and NT-proBNP, preventive antiplatelet therapy
may remain a reasonable option when indicated. In this
context it is important that these cardiac biomarkers attract
attention for guiding risk-centered preventive therapy.43,44
Nonetheless, whether the use of these cardiac markers would
actually guide better risk-benefit discussions should be tested
in future studies.
Our study has several limitations that should be considered
in the interpretation of our findings. First, we used ICD-9
hospitalization discharge codes for the diagnosis of bleeding
events, which are prone to misclassification. However, when
we used ICD-9 hospitalization codes with bleeding as the
primary reason for hospitalization, our findings were largely
consistent. Also, a recent landmark study quantified bleeding
events among populations without cardiovascular disease
using discharge ICD codes.32 Second, we did not capture mild
bleeding events that were managed only in the outpatient
setting. However, the majority of clinically significant bleeding
events are managed in the hospital.45 Also, our investigation
of more severe bleeding cases is important because they are
the major contributor to poor prognosis and increased costs.1
Third, our study is a community-based cohort of white and
black men and women aged 53 to 75 years, and thus our
results may not directly extrapolate to other age or racial/
ethnic groups or to specific clinical populations (eg, severely
reduced kidney function). Fourth, even though we adjusted for
the major predictors of bleeding, our study was observational,
and residual confounding could have still played a role in our
findings. For example, information on medications such as
aspirin, antiplatelet agents, and NSAIDs was based on the
clinical visits and annual phone follow-up, and thus we could
not capture intermittently used medications or medications
initiated just before bleeding if any.
Conclusions
Elevations of hs-cTnT and NT-proBNP in a community-based
population without prevalent cardiovascular disease at
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baseline were associated with future risks of major bleeding
events. These cardiac markers improved the prediction of
bleeding risk beyond conventional predictors, suggesting their
utility in identifying individuals at high bleeding risk. Research
into the underlying pathophysiological mechanisms behind
our observation may elucidate abnormal hemostatic mecha-
nisms in individuals with subclinical cardiac abnormalities and
may further guide prevention of bleeding.
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Table S1. Summary of ICD-9 hospital discharge codes used in the derivation of the outcome, hospitalization with bleeding. 
 
Outcome ICD-9 Code Specific diagnosis 
Upper gastrointestinal bleeding 532.xx Acute or chronic duodenal ulcer with hemorrhage 
 531.xx Acute or chronic gastric ulcer with hemorrhage 
 535.01, 535.31 Acute gastritis with hemorrhage 
 535.41 Other specified gastritis with hemorrhage 
 535.51 Unspecified gastritis and gastroduodenitis with hemorrhage 
 534.xx Acute or chronic gastrojejunal ulcer with hemorrhage 
 533.xx Acute or chronic peptic ulcer with hemorrhage 
 537.83 Angiodysplasia of stomach and duodenum with hemorrhage 
 537.84 Dieulafoy lesion (hemorrhagic) of stomach and duodenum 
 535.11 Atrophic gastritis with hemorrhage 
 535.61  Duodenitis with hemorrhage 
 530.21 Ulcer of the esophagus with bleeding 
 530.82 Esophageal hemorrhage 
 456.xx Esophageal varices with bleeding 
 456.2 Esophageal varices with bleeding diseases classified elsewhere 
 535.21 Gastric mucosal hypertrophy with hemorrhage (hypertrophic gastritis) 
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 530.7 Gastroesophageal laceration-hemorrhage syndrome (Mallory Weiss syndrome) 
 578.xx Hematemesis 
Lower gastrointestinal bleeding 569.85 Angiodysplasia of intestine with hemorrhage 
 569.86 Dieulafoy lesion (hemorrhagic) of intestine  
 562.13 Diverticulitis of colon with hemorrhage 
 562.03 Diverticulitis of small intestine with hemorrhage 
 562.12 Diverticulosis of colon with hemorrhage 
 562.02 Diverticulosis of small intestine with hemorrhage 
 569.3 Hemorrhage of rectum and anus 
Unspecified source 578.9 Hemorrhage of gastrointestinal tract, unspecified 
 578.1 Blood in stool 
Intracranial hemorrhage 430.0 Subarachnoid hemorrhage 
 431.0 Intracerebral hemorrhage 
 432.1 Subdural hemorrhage  
Retroperitoneal bleeding 459.0 Hemorrhage unspecified 
 793.6 Abnormal finding on imaging of the abdomen 
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Table S2. Baseline characteristics according to categories of NT-proBNP, the ARIC Study (1996-1998) (N=9,550). 
Baseline characteristics 
NT-proBNP 
<42 pg/mL 
NT-proBNP 42-
81 pg/mL 
NT-proBNP 81-
140 pg/mL 
NT-proBNP 140-
264 pg/mL 
NT-proBNP 
≥264 pg/mL 
p-values 
No. of participants 3,229 2,474 1,937 1,236 674  
Age, years 60.9 (5.2) 62.5 (5.5) 63.3 (5.5) 64.4 (5.8) 65.7 (5.4) <0.001 
Female 42.9% 61.3% 69.5% 72.3% 66.2% <0.001 
Black 30.7% 19.3% 15.7% 13.6% 16.2% <0.001 
Body mass index, kg/m2 29.4 (5.1) 28.7 (5.6) 28.2 (5.7) 28.0 (5.8) 28.2 (5.9) <0.001 
Family History of CAD 52.5% 56.8% 58.9% 60.4% 60.2% <0.001 
Education level      <0.001 
Basic 17.7% 16.7% 16.5% 18.5% 24.3%  
Intermediate 38.9% 43.7% 45.4% 43.3% 41.7%  
Advanced 43.3% 39.5% 38.2% 38.2% 34.0%  
Smoking status      <0.001 
Current smokers 13.9% 13.8% 14.1% 15.2% 19.3%  
Former smokers 44.6% 41.0% 40.0% 41.9% 42.0%  
Never smokers 41.5% 45.1% 45.8% 42.9% 38.7%  
Drinking status      <0.001 
Current drinkers 50.4% 52.4% 50.4% 49.7% 47.5%  
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Former drinkers 30.5% 26.0% 28.1% 26.9% 30.1%  
Never drinkers 19.0% 21.5% 21.5% 23.4% 22.4%  
Hs-cTnT, ng/L, median (IQR) 4.0 (1.5, 7.0) 1.5, 7.0 4.0 (1.5, 7.0) 5.0 (1.5, 8.0) 8.0 (4.0, 13.0) <0.001 
Systolic blood pressure, mmHg 123.2 (15.8) 126.2 (18.3) 128.6 (18.9) 131.5 (20.1) 137.5 (23.8) <0.001 
Total cholesterol, mmol/l 5.3 (1.0) 5.2 (0.9) 5.2 (0.9) 5.2 (0.9) 5.1 (1.0) <0.001 
HDL cholesterol, mmol/l 1.2 (0.4) 1.3 (0.4) 1.4 (0.5) 1.4 (0.5) 1.4 (0.5) <0.001 
eGFR categories in  
ml/min per 1.73m2 
     <0.001 
< 30 0.1% 0.1% 0.0% 0.2% 2.5%  
30 - 60 3.0% 4.9% 6.2% 8.0% 17.7%  
>60 97.0% 95.0% 93.8% 91.7% 79.8%  
AST, U/L, median (IQR) 18.0 (16.0, 22.0) 18.0 (15.0, 21.0) 18.0 (15.0, 21.0) 18.0 (15.0, 21.0) 18.0 (15.0, 21.0) <0.001 
ALT, U/L, median (IQR) 15.0 (11.0, 20.0) 13.0 (10.0, 18.0) 12.0 (9.0, 16.0) 12.0 (9.0, 15.0) 11.0 (9.0, 15.0) <0.001 
Medication use       
Hypertension medications 30.4% 30.0% 32.5% 38.5% 52.1% <0.001 
Aspirin 52.4% 53.6% 55.9% 55.0% 61.4% <0.001 
Statin 9.4% 8.5% 8.5% 8.3% 12.2% 0.03 
Anticoagulant 0.5% 0.8% 0.7% 1.2% 7.4% <0.001 
Diabetes mellitus 17.5% 14.5% 12.3% 11.7% 17.8% <0.001 
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History of hepatic failure 0.2% 0.1% 0.3% 0.2% 1.0% 0.002 
History of cancer 6.4% 8.9% 8.2% 9.4% 8.9% 0.001 
Values are mean  SD or percentage, unless otherwise indicated.  
eGFR (estimated glomerular filtration rate), AST (aspartate aminotransferase), ALT (alanine aminotransferase), CAD (coronary artery disease), HDL 
(high density lipoprotein), hs-cTnT (high sensitivity cardiac troponin T), NT-proBNP (N-terminal pro B-type natriuretic peptide). 
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Table S3. Hazard ratios (95% confidence intervals) for the association of baseline categories and log-transformed hs-cTnT (ng/L) and NT-
proBNP (pg/ml) with incident hospitalizations for bleeding as the primary discharge diagnosis, the ARIC Study. 
hs-cTnT  <3 3-6 6- <9  9- <14   ≥14 log hs-cTnT 
Model 1 Reference 0.82 (0.60 - 1.11) 1.26 (0.60 - 1.70) 1.68 (1.21 - 2.32) 2.20 (1.48 - 3.22) 1.32 (1.16 – 1.51) 
Model 2 Reference 0.81 (0.60 - 1.10) 1.25 (0.60 - 1.69) 1.67 (1.21 - 2.32) 2.13 (1.44 - 3.15) 1.30 (1.14 – 1.49) 
Model 3 Reference 0.81 (0.59 - 1.09) 1.25 (0.59 - 1.69) 1.66 (1.20 - 2.30) 2.08 (1.41 - 3.07) 1.29 (1.13 – 1.48) 
 NT-pro BNP <42 42- <81 81- <140 140- <264  ≥ 264 log NT-proBNP  
Model 1 Reference 1.31 (0.99 - 1.74) 1.34 (0.98 - 1.82) 1.40 (0.99 - 1.98) 1.97 (1.33 - 2.91) 1.20 (1.08 – 1.33) 
Model 2 Reference 1.31 (0.99 - 1.73) 1.33 (0.98 - 1.81) 1.39 (0.99 - 1.97) 1.93 (1.30 - 2.87) 1.19 (1.08 -1.32) 
Model 3 Reference 1.29 (0.98 - 1.72) 1.31 (0.96 - 1.78) 1.36 (0.96 - 1.93) 1.82 (1.22 - 2.71) 1.18 (1.06 – 1.30) 
 
Model 1 adjusted for age, sex, race-center, education, BMI, diabetes, family history of coronary artery disease, systolic blood pressure, cigarette use, 
alcohol use, total cholesterol, HDL cholesterol, statin use, aspirin, anticoagulation, NSAID, antihypertensive, eGFR, ACR, AST, ALT. 
Model 2 adjusted for variables in Model 1 and for hs-cTnT or NT-proBNP  
Model 3 adjusted for variables in Model 2 and incident stroke and coronary heart disease 
eGFR (estimated glomerular filtration rate), ACR (albumin creatinine ratio), AST (aspartate aminotransferase), ALT (alanine aminotransferase), HDL 
(high density lipoprotein), hs-cTnT (high sensitivity cardiac troponin T), HR (hazard ratio), NT-proBNP (N-terminal pro B-type natriuretic peptide). 
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Table S4. Hazard ratios and 95 % confidence intervals for the association of baseline categories and log-transformed hs-cTnT (ng/L) and NT-
proBNP (pg/ml) with incident hospitalizations for (a) gastrointestinal bleeding, (b) intracranial bleeding, (c) retroperitoneal bleeding in the 
ARIC Study. 
(a) 
hs-cTnT  <3 3-6 6- <9  9- <14   ≥14 log hs-cTnT 
Model 1 Reference 0.84 (0.67 - 1.04) 1.33 (1.06 - 1.65) 1.50 (1.18-1.90) 1.96 (1.47-2.60) 1.28 (1.16 – 1.41) 
Model 2 Reference 0.83 (0.67 - 1.04) 1.33 (1.08 - 1.64) 1.50 (1.18 - 1.90) 1.89 (1.43 - 2.53) 1.25 (1.13 – 1.38) 
Model 3 Reference 0.82 (0.66 - 1.02) 1.33 (1.07 - 1.64) 1.48 (1.16 - 1.88) 1.86 (1.39 - 2.47) 1.24 (1.13 – 1.37) 
 NT-pro BNP <42 42- <81 81- <140 140- <264  ≥ 264 log NT-proBNP 
Model 1 Reference 1.28 (1.05 - 1.57) 1.27 (1.01 - 1.57) 1.29 (0.99 - 1.65) 2.17 (1.65 - 2.86) 1.19 (1.11 – 1.28) 
Model 2 Reference 1.28 (1.05 - 1.57) 1.26 (1.01 - 1.58) 1.28 (0.99 - 1.65) 2.14 (1.63 - 2.83) 1.19 (1.10 – 1.28) 
Model 3 Reference 1.26 (1.03 - 1.56) 1.24 (0.99 - 1.55) 1.27 (0.99 - 1.64) 2.01 (1.53 - 2.66) 1.16 (1.08 – 1.26) 
(b) 
hs-cTnT  <3 3-6 6- <9  9- <14   ≥14 log hs-cTnT 
Model 1 Reference 0.47 (0.16 - 1.38) 1.14 (0.47 - 2.78) 1.94 (0.79 - 4.74) 1.94 (0.65 - 5.80) 1.42 (0.95 – 2.11) 
Model 2 Reference 0.47 (0.16 - 1.38) 1.14 (0.47 - 2.75) 1.94 (0.79 - 4.74) 1.89 (0.63 - 5.70) 1.40 (0.93 – 2.10) 
Model 3 Reference 0.46 (0.16 - 1.36) 1.14 (0.47 - 2.76) 1.92 (0.78 - 4.70) 1.93 (0.64 - 5.81) 1.41 (0.93 – 2.13) 
 NT-pro BNP <42 42- <81 81- <140 140- <264  ≥ 264 Log NT-proBNP 
Model 1 Reference 1.13 (0.52 - 2.43) 0.99 (0.41 - 2.41) 0.95 (0.34 - 2.62) 1.49 (0.48 - 4.65) 1.06 (0.80 – 1.41) 
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Model 2 Reference 1.13 (0.52 - 2.43) 0.99 (0.41 - 2.41) 0.95 (0.34 - 2.61) 1.48 (0.47 - 4.64) 1.06 (0.80 – 1.41) 
Model 3 Reference 1.11 (0.51 - 2.34) 0.97 (0.40 - 2.34) 0.95 (0.35 - 2.63) 1.44 (0.46 - 4.57) 1.05 (0.79 – 1.40) 
(c) 
hs-cTnT  <3 3-6 6- <9  9- <14   ≥14 Continuous hs-cTnT 
Model 1 Reference 0.91(0.34 - 2.42) 0.38 (0.08 - 1.80) 2.38 (0.80 - 7.03) 4.23 (1.21 - 14.84) 1.33 (0.83 – 2.14) 
Model 2 Reference 0.91 (0.34 - 2.41) 0.38 (0.08 - 1.79) 2.37 (0.80 - 7.00) 4.16 (1.17 - 14.84) 1.32 (0.82 – 2.13) 
Model 3 Reference 0.91 (0.34 - 2.42) 0.38 (0.08 - 1.81) 2.42 (0.82 - 7.15) 4.30 (1.20 - 15.35) 1.34 (0.82 – 2.19) 
 NT-pro BNP <42 42- <81 81- <140 140- <264  ≥ 264 Continuous NT-proBNP 
Model 1 Reference 1.49 (0.50 - 4.46) 1.59 (0.50 - 5.10) 2.24 (0.68 - 7.40) 2.58 (0.62 - 10.67) 1.36 (0.93 – 2.00) 
Model 2 Reference 1.49 (0.50 - 4.45) 1.59 (0.50 - 5.09) 2.23 (0.68 - 7.38) 2.55 (0.61 - 10.59) 1.36 (0.92 – 2.00) 
Model 3 Reference 1.49 (0.50 - 4.45) 1.58 (0.49 - 5.07) 2.23 (0.67 - 7.39) 2.58 (0.62 - 10.75) 1.36 (0.93 – 2.01) 
 
Model 1 adjusted for age, sex, race-center, education, BMI, diabetes, family history of coronary artery disease, systolic blood pressure, cigarette use, 
alcohol use, total cholesterol, HDL cholesterol, statin use, aspirin, anticoagulation, NSAID, antihypertensive, eGFR, ACR, AST, ALT. 
Model 2 adjusted for variables in Model 1 and for hs-cTnT or NT-proBNP  
Model 3 adjusted for variables in Model 2 and incident stroke and coronary heart disease 
Abbreviations: eGFR (estimated glomerular filtration rate), ACR (albumin creatinine ratio), AST (aspartate aminotransferase), ALT (alanine 
aminotransferase), HDL (high density lipoprotein), hs-cTnT (high sensitivity cardiac troponin T), HR (hazard ratio), NT-proBNP (N-terminal pro B-type 
natriuretic peptide). 
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Table S5. Hazard ratios (95% confidence intervals) for the association of baseline categories and log-transformed hs-cTnT (ng/L) and NT-
proBNP (pg/ml) with incident hospitalizations for bleeding, the ARIC Study. Patients with prevalent bleeding at visit 4 included. 
hs-cTnT  <3 3-6 6- <9  9- <14   ≥14 log hs-cTnT 
Model 1 Reference 0.80 (0.65 - 0.99) 1.29 (1.05 - 1.59) 1.52 (1.21 - 1.91) 2.05 (1.57 - 2.69) 1.35 (1.23 – 1.48) 
Model 2 Reference 0.80 (0.64 - 0.98) 1.29 (1.05 - 1.58) 1.52 (1.21 - 1.91) 1.99 (1.52 - 2.62) 1.28 (1.17 – 1.41) 
Model 3 Reference 0.78 (0.64 - 0.97) 1.29 (1.05 - 1.58) 1.51 (1.20 - 1.89) 1.95 (1.49 - 2.56) 1.26 (1.14 – 1.38) 
Model 4 Reference 0.78 (0.64 - 0.97) 1.29 (1.05 - 1.58) 1.50 (1.20 - 1.89) 1.95 (1.48 - 2.60) 1.25 (1.14 – 1.36) 
 NT-pro BNP <42 42- <81 81- <140 140- <264  ≥ 264 log NT-proBNP 
Model 1 Reference 1.29 (1.06 - 1.57) 1.26 (1.02 - 1.57) 1.28 (1.01 - 1.64) 2.14 (1.64 - 2.79) 1.22 (1.14 – 1.31) 
Model 2 Reference 1.29 (1.06 - 1.56) 1.26 (1.02 – 1.56) 1.28 (1.00 - 1.63) 2.12 (1.62 - 2.76) 1.18 (1.10 – 1.27) 
Model 3 Reference 1.27 (1.05 - 1.55) 1.24 (1.00 - 1.54) 1.26 (0.99 - 1.60) 2.00 (1.53 - 2.61) 1.18 (1.10 – 1.27) 
Model 4 Reference 1.27 (1.05 - 1.55) 1.24 (1.00 - 1.53) 1.25 (0.98 – 1.60) 2.00 (1.53 - 2.61) 1.16 (1.08 – 1.25) 
 
Model 1 adjusted for age, sex, race-center, education, BMI, diabetes, family history of coronary artery disease, systolic blood pressure, cigarette use, 
alcohol use, total cholesterol, HDL cholesterol, statin use, aspirin, anticoagulation, NSAID, antihypertensive, eGFR, ACR, AST, ALT. 
Model 2 adjusted for variables in Model 1 and for hs-cTnT or NT-proBNP  
Model 3 adjusted for variables in Model 2 and incident stroke and coronary heart disease 
Model 4 adjusted for variables in Model 3 and history of prevalent bleeding 
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eGFR (estimated glomerular filtration rate), ACR (albumin creatinine ratio), AST (aspartate aminotransferase), ALT (alanine aminotransferase), HDL 
(high density lipoprotein), hs-cTnT (high sensitivity cardiac troponin T), HR (hazard ratio), NT-proBNP (N-terminal pro B-type natriuretic peptide). 
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